US3984384087 - ADR
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to...
NEW YORK, NY - (NewMediaWire) - August 31, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK, NY - (NewMediaWire) - August 29, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK, NY - (NewMediaWire) - August 27, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK, NY - (NewMediaWire) - August 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK, NY - (NewMediaWire) - July 31, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK, NY - (NewMediaWire) - July 30, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to...
Finding stocks to buy and hold for the long haul is sometimes as easy as grabbing a few suggestions from a seasoned investment pro.
Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Grifols (NASDAQ:GRFS) stock is jumping on Monday after investors learned that t...
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to know about on Monday!
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo...
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that...